2019-003082-17: How electronic monitoring and feedback affect use of Easyhaler asthma medication. Wie sich elektronische Kontrolle und Rückmeldung auf die Einnahme der Easyhaler-Asthmamedikation auswirken |
|
|
| Not yet recruiting | 4 | 166 | Europe | Inhalation powder, Budesonid Orion Easyhaler 0,2 mg/Dosis, Budesonid Orion Easyhaler 0,4 mg/Dosis, Bufori Easyhaler 160 Mikrogramm/4,5 Mikrogramm, Bufori Easyhaler 320 Mikrogramm/9 Mikrogramm, Flusarion Easyhaler 50 Mikrogramm/250 Mikrogramm, Flusarion Easyhaler 50 Mikrogramm/500 Mikrogramm, Salbu Easyhaler 0,2 mg/Dosis | Orion Corporation Orion Pharma, Orion Corporation Orion Pharma | Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2021-001573-22: Use of Buventol and Bufomix Easyhaler in methacholine challenge andtheir effect on inhalation profiles in experimentally induced asthma attacks Buventol ja Bufomix Easyhalerin käyttö metakoliinialtistuksen avaavana lääkkeenä sekä niiden vaikutus sisäänhengitysprofiileihin kokeellisesti aiheutetussa astmakohtauksessa |
|
|
| Not yet recruiting | 4 | 180 | Europe | Buventol® Easyhaler® 200 µg/dose inhalation powder, Bufomix® Easyhaler® 160/4.5µg/inhalation, inhalation powder, Ventoline® Evohaler® 100 µg/inhalation pMDI, Inhalation powder, Inhalation solution, Buventol® Easyhaler® 200 µg/dose inhalation powder, Bufomix® Easyhaler® 160/4.5µg/inhalation, inhalation powder, Ventoline® Evohaler® 100 µg/inhalation | Orion Corporation, Orion Corporation | Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Completed | 4 | 180 | Europe | Buventol® Easyhaler® 200 µg/inhalation dmDPI, Salbutamol 200 µg/dose dmDPI, Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI, Budesonide/formoterol 160/4.5 µg/inhalation dmDPI, Ventoline® Evohaler® 100 µg/inhalation pMDI, Salbutamol 100 µg/dose MDI | Orion Corporation, Orion Pharma | Asthma | 06/23 | 06/23 | | |
